Newborn bloodspot screening policy framework for Australia.

BACKGROUND The aim of newborn bloodspot screening (NBS) is to identify rare genetic and non-genetic conditions in children soon after birth in order to commence therapies that prevent the development of progressive, serious, and irreversible disabilities. Universal NBS programmes have been implemented in most countries, with minor adaptations to target conditions most relevant to the local healthcare environment. AIMS In this article, we describe the initiatives of international and Australian governments to develop policies to address the expansion of NBS in their healthcare systems. METHODS We have reviewed published public policies and literature to formulate recommendations based on clinical, social, legal, and ethical principles to inform a national governance and policy framework for Australia. RESULTS Australian policy makers have been slow to develop a coordinated plan. While the experience from other governments can guide our national policy, there are specific areas that require further consideration by Australian health experts. Key reforms involve the separation of policy and operational activities, multidisciplinary decision-making and oversight by the Australian Health Ministers' Advisory Council for policy direction. CONCLUSION A formal national policy framework will guide the coordination of NBS services that can adapt to the needs of Australian children and families.

[1]  J. Gray,et al.  Evidence based policy making , 2004, BMJ : British Medical Journal.

[2]  B. Wilfond,et al.  Parental Permission for Pilot Newborn Screening Research: Guidelines From the NBSTRN , 2014, Pediatrics.

[3]  S. Warren,et al.  Newborn screening for developmental disabilities: reframing presumptive benefit. , 2005, American journal of public health.

[4]  J. Bonham Impact of new screening technologies: should we screen and does phenotype influence this decision? , 2013, Journal of Inherited Metabolic Disease.

[5]  B. Kosofsky,et al.  Newborn screening for Krabbe disease: the New York State model. , 2009, Pediatric neurology.

[6]  D. Fitzgerald,et al.  Long-term outcomes of children with intermediate sweat chloride values in infancy. , 2015, The Journal of pediatrics.

[7]  Domenica Taruscio,et al.  A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document , 2013, European Journal of Human Genetics.

[8]  A. Andermann,et al.  Guiding Policy Decisions for Genetic Screening: Developing a Systematic and Transparent Approach , 2009, Public Health Genomics.

[9]  J. Puck,et al.  Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. , 2002, Blood.

[10]  H. Dawkins,et al.  New mothers' awareness of newborn screening, and their attitudes to the retention and use of screening samples for research purposes , 2005, Genomics, society, and policy.

[11]  John J. Mitchell,et al.  Achieving the “triple aim” for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework , 2012, Genetics in Medicine.

[12]  D. Taruscio,et al.  Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance , 2012, Journal of Inherited Metabolic Disease.

[13]  B. Potter,et al.  Newborn Screening by Tandem Mass Spectrometry , 2007, Canadian journal of public health = Revue canadienne de sante publique.

[14]  R. Guthrie,et al.  A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS. , 1963, Pediatrics.

[15]  P. O'Leary,et al.  Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism , 2005, Journal of paediatrics and child health.

[16]  D. Studdert,et al.  Newborn screening cards: a legal quagmire , 2011, The Medical journal of Australia.

[17]  D. Amor,et al.  Implementation of written consent for newborn screening in Victoria, Australia , 2014, Journal of paediatrics and child health.

[18]  K. Wilson,et al.  Developing a National Newborn Screening Strategy for Canada , 2010 .

[19]  Gary L Hoffman,et al.  Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project , 2011, Genetics in Medicine.

[20]  A. Woodhouse Evidence and practice. , 2005, Mental health today.

[21]  E. Haan,et al.  Human Genetics Society of Australasia Position Statement: Population-Based Carrier Screening for Cystic Fibrosis , 2014, Twin Research and Human Genetics.

[22]  Jennifer Couzin-Frankel,et al.  Science Gold Mine, Ethical Minefield , 2009, Science.

[23]  B. Wilcken,et al.  Screening newborns for inborn errors of metabolism by tandem mass spectrometry. , 2003, The New England journal of medicine.

[24]  D. Atkins,et al.  Making policy when the evidence is in dispute. , 2005, Health affairs.

[25]  S. Timmermans,et al.  Newborn screening and maternal diagnosis: rethinking family benefit. , 2011, Social science & medicine.

[26]  David Holmes Europe plays catch-up on neonatal screening as US skips ahead , 2012, Nature Medicine.

[27]  B. Wilcken,et al.  Fifty years of newborn screening , 2015, Journal of paediatrics and child health.